institut merieux

Institut Mérieux Strengthens its Commitment to Medicine and Global Public Health

    Paris (ots/PRNewswire) - Institut Mérieux strengthens its commitment to medicine and global public health via an ambitious innovation policy, the structuring of a food safety/nutrition hub and the creation of a company dedicated to diagnostics in developing countries.

    One year after reinstating the historic name of Institut Mérieux for the family holding devoted to industrial biology, Alain Mérieux and the management teams of the companies, bioMérieux, Transgene, Mérieux Nutrisciences and Mérieux Développement, have presented the actions implemented within the scope of their innovation and international development strategy with:

@@start.t1@@      - the structuring of a food safety/nutrition hub based around Mérieux
         NutriSciences, completing and supporting the diagnostic and therapeutic
         Areas covered by Institut Mérieux
      - the Group's innovation policy with, in particular, the first holdings
         by its investment company, Mérieux Développement
      - the development of biology accessible to all with the creation of
         IMAccess, a not-for-profit company devoted to diagnostics in developing

    "Institut Mérieux has undergone considerable changes to address the new global challenges in medicine and public health. The arrival of Jean-Luc Bélingard as Président Directeur Général of bioMérieux and Vice-President of Institut Mérieux will enable me to devote more time to Institut Mérieux and the Mérieux foundations", stated Alain Mérieux. "Now, more than ever, scientific innovation, multidisciplinary approaches and international development are at the heart of our strategy. In an ever-changing healthcare environment, with infectious disease representing a constant threat, the emergence of new risks associated with food and now better known interactions between infectious diseases, cancers and nutrition, we have made sure we have new resources to achieve our long-term targets. The structuring of a nutrition/health hub, which is highly complementary to our therapeutic and diagnostic activities, is a strong example. Our innovation strategy is also taking form with Mérieux Développement and a stronger international network of scientific experts. Finally, IMAccess aims to offer a complementary approach to conventional models, to make quality biology and diagnostics accessible to the greatest number and thus combat infectious diseases, with no borders between North and South."

    Institut Mérieux prioritizes nutrition  

    Institut Mérieux is increasing its commitment in the area of food safety and nutrition by structuring a food safety/nutrition hub based around Mérieux NutriSciences. With Silliker, its very first company in the field of food safety, Biofortis and Bioagri, Mérieux Nutrisciences is now developing an end-to-end offering to meet the needs of players in the food processing chain: raw material and environmental safety and conformity, food quality, R&D and clinical trial program in the area of nutrition to help develop foods offering a health benefit.

    The originality and strength of the Mérieux NutriSciences approach lie in the combination of Silliker's know-how in the food sector with Institut Mérieux's scientific expertise and international network, making it possible to include a medical vision and a public health dimension in all its activities.

    With its financial structure strengthened by an increase in the subscribed capital by Institut Mérieux in 2010, Mérieux NutriSciences can envisage a relevant acquisition policy and speed up its international roll-out strategy, particularly in emerging countries such as China, India and Brazil.

    Major advances in Institut Mérieux's innovation policy  

    One year after it was founded, Mérieux Développement has announced three minority holdings in innovative companies in the health sector:

@@start.t2@@      - Supersonic Imagine, a French company based in Aix-en-Provence, which
         markets a new generation ultrasonic scanner, equipped with a cutting-
         edge imaging technique (ultrasound elastography), thus opening up
         further clinical applications in oncology, for diagnosis and
         characterization of lesions (breast, thyroid, liver, prostate).
      - QuantaLife, a Californian company, whose Droplet Digital(TM) PCR
         technology represents major progress in the area of molecular biology,
         in terms of sensitivity and precision, making it possible to offer
         multiple applications in human genetics and, in the medium term, an
         effective instrumentation solution for cancer and infectious disease
      - Biom'Up, a French company based in Lyon, marketing innovative
         biomaterials and implantable medical devices for surgery and developing
         a new range of products (guided regeneration, adherence prevention and
         hemostasis), aimed at patient comfort and safety and simplified
         surgical procedures.@@end@@

    In the course of 2010, Mérieux Développement set up an international cooperation and joint investment network, along with a special partnership with the French Commissariat à l'Energie Atomique (CEA). The purpose of this partnership is support businesses developing high added medical value products, by means of an original approach based on complementary expertise and close cooperation with CEA Investissement.

    The Mérieux Research Grants program steps up a gear. These grants are awarded to projects from leading researchers and clinicians in areas of strategic interest for Institut Mérieux: diagnostics, therapy and nutrition. Since the program was launched in 2009, over 20 grants have been awarded to researchers from public or private laboratories, in North America, Europe and Asia, on topics offering strong potential for the Group. This program helps strengthen Institut Mérieux's scientific network of experts around the world and give bioMérieux, Transgene and Mérieux NutriSciences access to clinical and technological advances which will be the source of new diagnostic tests and new therapies.

    Serving global public health since its inception, Institut Mérieux is increasing its action in developing countries through the creation of IMAccess.

    With IMAccess, Institut Mérieux, in keeping with its tradition, is seeking to place its expertise in infectious disease and its bio-industrial experience at the service of diagnostics accessible to the greatest number.

    A 100% subsidiary of Institut Mérieux, this new company is dedicated to the development, production and supply of rapid diagnostic tests, for governments, international health organizations, NGOs, etc.

    These tests, complying with the most exacting international quality standards and adapted to the frequently extreme constraints associated with use in the field, focus on diseases which are having a severe impact on underprivileged countries, such as AIDS, dengue, meningitis, malaria, Leishmaniasis, etc. The first products should be available in 2012.

    IMAccess essentially relies on research and development teams based in France, Brazil and China, along with the Group's expertise in bioproduction and its distribution network.

    In order to speed up the development of these tests and make them accessible in terms of price, IMAccess has adopted an original social business model, a not-for-profit company, reinvesting all its profits in its R&D programs.

    About Institut Mérieux  

    Institut Mérieux is committing its experience in industrial biology to serve medicine and public health across the globe. To fight against infectious diseases and cancers, it imagines and develops new approaches in the fields of diagnostics, immunotherapy, food safety and nutrition.

    Through its three bio-industrial companies, bioMérieux, Transgene and Mérieux NutriSciences , working closely with its entities devoted to innovation (Mérieux Développement and ABL Inc.), Institut Mérieux has the potential to offer solutions for new global public health challenges:

    bioMérieux is listed on Euronext, represents a 59% holding and is based in Marcy l'Etoile (France). A global player in the area of in vitro diagnostics and industrial microbiological testing, bioMérieux employs 6300 people and generated sales of EUR1.223 billion in 2009. It is present in 150 countries with a network of 39 subsidiaries.

    Transgene is listed on Euronext, represents a 55% holding and is based in Strasbourg (France). This biotechnology company specialized in immunology applied to the treatment cancers and infectious diseases employs 280 people in its programs.

    Mérieux NutriSciences represents an 89% holding and is based in Chicago (USA): it is a service company specialized in improving food safety and nutrition. With a staff of 4000, Mérieux NutriSciences is, with its three units, Silliker, Biofortis and Bioagri, now present in 16 countries,via close to 60 accredited laboratories and represents sales totaling over $350 million.

    Advanced BioScience Laboratories Inc (ABL Inc): this company is 100% owned by Institut Mérieux. Based in Washington DC (USA), it employs over 100 people in virology R&D programs.

    Mérieux Développement: a company investing in the area of health, 100% owned by Institut Mérieux and based in Lyon (France).

    Institut Mérieux employs over 10,000 people committed to global public health and generates sales in excess of EUR1.4 billion.

ots Originaltext: institut merieux
Im Internet recherchierbar:

CONTACT:  Press contacts: Institut Mérieux, Anne de
Image 7, LaurenceHeilbronn 01-53-70-74-64,
Albane de La Tour d'Artaise01-53-70-74-84

Weitere Meldungen: institut merieux

Das könnte Sie auch interessieren: